XML 23 R5.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Previously Reported [Member]
Convertible Preferred Stock
Convertible Preferred Stock
Previously Reported [Member]
Common Stock
Common Stock
Previously Reported [Member]
Additional Paid-in Capital
Additional Paid-in Capital
Previously Reported [Member]
Accumulated Deficit
Accumulated Deficit
Previously Reported [Member]
Accumulated other comprehensive income (loss)
Balance at the beginning at Dec. 31, 2019 $ (44,429) $ (44,429)         $ 1,104 $ 1,104 $ (45,533) $ (45,533)  
Balance (in Shares) at Dec. 31, 2019         4,865,000 996,000          
Balance at the beginning at Dec. 31, 2019     $ 46,206 $ 46,206              
Balance (in Shares) at Dec. 31, 2019     74,159,000 15,181,000              
Retroactive application of exchange ratio, Shares at Dec. 31, 2019       58,978,000   3,869,000          
Issuance of Series C Preferred Stock for cash, net of offering costs     $ 57,439                
Issuance of Series C Preferred Stock for cash, net of offering costs (in Shares)     26,946,000                
Conversion of Convertible Note to Series C-1 Preferred Stock     $ 7,787                
Conversion of Convertible Note to Series C-1 Preferred Stock (in Shares)     3,717,000                
Issuance of common stock in connection with acquisition 813           813        
Issuance of common stock in connection with acquisition (in Shares)         1,373,000            
Exercise of warrants (in Shares)         15,000            
Stock-based compensation 1,759           1,759        
Stock-based compensation (in Shares)         4,123,000            
Common stock warrants related to marketing expense 481           481        
Net loss (37,109)               (37,109)    
Other comprehensive loss 235                   $ 235
Balance at the end at Dec. 31, 2020 (78,250)           4,157   (82,642)   235
Balance (in Shares) at Dec. 31, 2020         10,376,000            
Balance at the end at Dec. 31, 2020     $ 111,432                
Balance (in Shares) at Dec. 31, 2020     104,822,000                
Issuance of Series C Preferred Stock for cash, net of offering costs     $ 34,793                
Issuance of Series C Preferred Stock for cash, net of offering costs (in Shares)     16,404,000                
Exercise of warrants 5           5        
Exercise of warrants (in Shares)         2,457,000            
Stock-based compensation 8,131           8,131        
Conversion of Convertible Preferred Stock to Common Stock 146,225   $ (146,225)   $ 13   146,212        
Conversion of Convertible Preferred Stock to Common Stock, shares     (121,226,000)   121,226,000            
Redemption of warrants, Shares         148,000            
Common stock warrants issued to customers as consideration 121           121        
Common stock warrants related to marketing expense 810           810        
Reverse recapitalization, net of transaction costs 444,647       $ 6   444,641        
Reverse recapitalization, net of transaction costs, Shares         59,657,000            
Net loss (71,961)               (71,961)    
Other comprehensive loss (226)                   (226)
Balance at the end at Dec. 31, 2021 449,502       $ 19   604,077   (154,603)   9
Balance (in Shares) at Dec. 31, 2021         193,864,000            
Balance at the end at Dec. 31, 2021                    
Balance (in Shares) at Dec. 31, 2021 0   0                
Exercise of warrants $ 3           3        
Exercise of warrants (in Shares)         1,874,000            
Stock-based compensation 13,716           13,716        
Tax withholdings related to net share settlement of equity awards (4,045)           (4,045)        
Tax withholdings related to net share settlement of equity awards, (in Shares)         907,000            
Issuance of common stock upon vesting of equity awards 1       $ 1            
Issuance of common stock upon vesting of equity awards ,(in Shares)         3,026,000            
Common stock warrants issued to customers as consideration 72           72        
Common stock warrants related to marketing expense 217           217        
Reverse recapitalization, net of transaction costs (70)           (70)        
Exercise of options 219           219        
Exercise of options (in Shares)         465,000            
Net settlement related to exercise of options (33)           (33)        
Net settlement related to exercise of options, (in Shares)         (5,000)            
ESPP Purchases 1,125           1,125        
ESPP Purchases (in shares)         208,000            
Net loss (96,322)               (96,322)    
Other comprehensive loss (185)                   (185)
Balance at the end at Dec. 31, 2022 364,200       $ 20   $ 615,281   $ (250,925)   $ (176)
Balance (in Shares) at Dec. 31, 2022         198,525,000            
Balance at the end at Dec. 31, 2022                    
Balance (in Shares) at Dec. 31, 2022 0   0